Cardiovascular Risks and Urinary Albumin Excretion(UAE) in Polycystic Ovarian Syndrome (PCO)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02569164|
Recruitment Status : Unknown
Verified October 2015 by suzy abdelaziz Abdelhamid, Kasr El Aini Hospital.
Recruitment status was: Not yet recruiting
First Posted : October 6, 2015
Last Update Posted : October 6, 2015
|Condition or disease|
|Urinary Albumin Excretion|
PCO patients with 2 of 3 criteria: oligo- or anovulation ; hyperandrogenism &polycystic ovaries. Exclusion criteria: pregnancy, diabetes, hypertension , adrenal & thyroid dysfunction.
Blood samples after overnight fast (8hrs) at day 2 or 3 of menstrual cycle. Serum concentration of follicle stimulating hormone (FSH), luteinizing hormone (LH), prolactin, total testosterone & sex hormone binding globulin, serum 17-hydroxy (OH) progesterone & dehydroepiandrosterone sulfate will be measured.
Oral glucose tolerance test & plasma insulin levels will be measured. Total cholesterol, triglycerides, high& low density lipoproteins. Urinary albumin will be measured& all the data will be analysed.
|Study Type :||Observational|
|Estimated Enrollment :||50 participants|
|Official Title:||Urinary Albumin Excretion in Women With Polycyclic Ovary Syndrome and it's Relation to Cardiovascular Risk Factors|
|Study Start Date :||October 2015|
|Estimated Primary Completion Date :||November 2015|
|Estimated Study Completion Date :||December 2015|
- Number of patients with hyperinsulinemia (uIU/ml) [ Time Frame: 3 months ]
- Number of patients with hyperlipidemia (mg/dl). [ Time Frame: 3 months ]
- Number of patients with albuminuria(ug/ml) [ Time Frame: 3 months ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02569164
|Contact: suzy abdelaziz, M.D.||firstname.lastname@example.org|
|Principal Investigator:||suzy abdelaziz, M.D.||kasrelaini|